Exchange: NASDAQ·Updated 07:44 PM EST
LTRN logo

LTRN Lantern Pharma Inc

$0.245
$0.0389
(13.70%)
Today
Closed $0.245
$0.015
(6.12%)
After Hours
Reported EarningsNov 18
Mkt Cap$3.89M
Vol238,461.00

About LTRN

Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.
63

Bullish Sentiment

How do you feel about LTRN?

wells3600
$LTRN no matter what I say or what y'all say when 184 goes to Phase 3 Drug Trial ltrm will hit 45 dollar's
1
3
SevenPhigs27
$LTRN The assets far outweigh the PPS. It's laughable. One of the board members sold a company for billions. I'd keep an eye out.
3
wells3600
$LTRN I had to buy, .4765 1000 shares can't pass it by, I fill guilty, you dont lose if you don't sell.
1
1
BabetteCH
$LTRN Panna doesn’t have time to deliver the numbers on time or close deals. He’s too busy liking every single linkedIn-post. 🤣😂
1
1
wells3600
$LTRN Right now at, .28 x 6= 1.68 on big pharma deal ,that's what they offer plus percent lp-300 is ready to sell phase 2, now, oh and they have 14 million shares out ,that's about 23 million plus percent, They are not out for the count, AI portal spin off forgot, I no going there right now. Mr Ripper.
2
AtariLynx
$LTRN Contrary to what happened last March, the market might react positively to Sharma’s (genuine news this time) resignation. LET’S GO LANTERN PHARMA! BACK OVER $ 3 SOOOOOOOOOOOOOOOOON!!!!!’
2
AtariLynx
$LTRN “…. However, the presence of engaged institutional investors and insider buying suggests some conviction in the company’s AI-driven oncology platform and pipeline potential. Investors should weigh these qualitative factors alongside the company’s operational updates and clinical progress. For ongoing updates and comprehensive data, explore the LTRN stock page.” A NEW BEGINNING FOR LANTERN!
2
AtariLynx
$LTRN Lantern Pharma Announces Peer-Reviewed Publication of Phase 1a LP-184 Data in Recurrent Glioblastoma, Supporting a Phase 1b/2a Combination Trial with Spironolactone.
2
annapurna789
$LTRN nice move - trying to see if i can find any related news to explain it - volume is not particularly huge
2
Mack_The_Ripper
$LTRN he appeared to me to be very untrustworthy. And incompetent. Not cut out for the job. Too bad it took this long to make the change.
1

Advertisement|Remove ads.